Palivizumab for the prevention of respiratory syncytial virus infection

被引：0

作者：

Rogovik, Alexander L. ^{[1
]}

Carleton, Bruce ^{[1
]}

Solimano, Alfonso ^{[1
]}

Goldman, Ran ^{[1
]}

机构：

[1] British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC V6H 3V4, Canada

来源：

CANADIAN FAMILY PHYSICIAN | 2010年 / 56卷 / 08期

关键词：

COST-EFFECTIVENESS; YOUNG-CHILDREN; PROPHYLAXIS; SAFETY; RISK;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

QUESTION Palivizumab, a specific monoclonal antibody for respiratory syncytial virus (RSV), is available for prevention of pediatric respiratory tract infections. What are the indications for its use and can it be used for treatment of RSV infections? ANSWER Most infants should not be considered for RSV prophylaxis with palivizumab. The drug is approved for use for different indications in different Canadian provinces. The drug should be administered only in the context of infants most vulnerable to severe RSV illness with a high likelihood of hospital admission, particularly in the first 6 months of life. It is not effective in the treatment of RSV disease and it is not approved or recommended for this indication.

引用

页码：769 / 772

页数：3

共 14 条

[1]

Bocchini JA, 2009, PEDIATRICS, V124, P1216, DOI [10.1542/peds.2009-1806, 10.1542/peds.2009-2345]

[2] Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease [J].

ElHassan, Nahed O. ;

Sorbero, Melony E. S. ;

Hall, Caroline B. ;

Stevens, Timothy P. ;

Dick, Andrew W. .

ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2006, 160 (10) :1070-1076

[3] Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease [J].

Feltes, TF ;

Cabalka, AK ;

Meissner, C ;

Piazza, FM ;

Carlin, DA ;

Top, FH ;

Connor, EM ;

Sondheimer, HM .

JOURNAL OF PEDIATRICS, 2003, 143 (04) :532-540

[4] Preventing RSV bronchiolitis in vulnerable infants: The role of palivizumab [J].

Fitzgerald, Dominic A. .

PAEDIATRIC RESPIRATORY REVIEWS, 2009, 10 (03) :143-147

[5] Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus [J].

Johnson, S ;

Oliver, C ;

Prince, GA ;

Hemming, VG ;

Pfarr, DS ;

Wang, SC ;

Dormitzer, M ;

OGrady, J ;

Koenig, S ;

Tamura, JK ;

Woods, R ;

Bansal, G ;

Couchenour, D ;

Tsao, E ;

Hall, WC ;

Young, JF .

JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (05) :1215-1224

[6] Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection [J].

Lacaze-Masmonteil, T ;

Seidenberg, J ;

Mitchell, I ;

Cossey, V ;

Cihar, M ;

Csader, M ;

Baarsma, R ;

Valido, M ;

Pollack, PF ;

Groothuis, JR .

DRUG SAFETY, 2003, 26 (04) :283-291

[7] Beyond randomized controlled trials: A "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab [J].

Mitchell, Ian ;

Tough, Suzanne ;

Gillis, Lynne ;

Majaesic, Carina .

PEDIATRIC PULMONOLOGY, 2006, 41 (12) :1167-1174

[8] Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children - A UK analysis [J].

Nuijten, Mark J. C. ;

Wittenberg, Wolfgang ;

Lebmeier, Maximilian .

PHARMACOECONOMICS, 2007, 25 (01) :55-71

[9]

Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531

[10] Safety and immunogenicity of palivizumab (Synagis) administered for two seasons [J].

Null, D ;

Pollara, B ;

Dennehy, PH ;

Steichen, J ;

Sánchez, PJ ;

Givner, LB ;

Carlin, D ;

Landry, B ;

Top, FH ;

Connor, E .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (11) :1021-1023

← 1 2 →